Conquering the Solid Frontier: Next-Generation CAR-T Cell Immunotherapy Beyond Hematologic Malignancies - Transformative Strategies, Emerging Targets, and Future Paradigms

Abstract

Chimeric antigen receptor T-cell therapy has revolutionized the management of blood cancers yet its application in solid tumors has been restricted because of the complicated tumor microenvironment, differences in tumor antigens and effective immune-evasion strategies. Recent developments are concerned with advanced engineering practices in order to overcome these problems. Cytokine releasing (interleukin-12 or interleukin-18) armored chimeric antigen receptor T cells activate immune responses in suppressive tumor microclimates. Designs of logic-gated chimeric antigen receptor which need two antigen recognition improve tumor specificity and minimize harm to normal tissues. Metabolic and epigenetic reprogramming strategies are being created to enhance the survival of chimeric antigen receptor T-cells, retain stem-like features, and be able to function in low-oxygen and nutrient-deprived environments. Mesothelin, glypican-3, human epidermal growth factor receptor-2, mucin-1, and B7-H3 are some of the new tumor-associated targets that are broadening therapeutic opportunities in various solid tumors. The tools of synthetic biology, such as inducible promoters and self-regulating feedback controls, can enable the accurate regulation of the activation of chimeric antigen receptor T- cells and enhance safety. Also, artificial intelligence, personalized antigen profiling, and optimization based on biomarkers are integrated to develop highly customized chimeric antigen receptor T-cell products. The combination of these innovations is a significant change to more potent, multi-purpose, and smartly designed T-cell therapies that can destroy the obstacles of solid tumor.